Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
883.2 USD | -0.84% | -1.52% | +0.56% |
26/04 | Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says | MT |
26/04 | Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 | MT |
Business Summary
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Number of employees: 13,450
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Medicines
100.0
%
| 12,173 | 100.0 % | 13,117 | 100.0 % | +7.76% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
51.5
%
| 6,821 | 56.0 % | 6,754 | 51.5 % | -0.98% |
Rest of World
44.4
%
| 4,987 | 41.0 % | 5,827 | 44.4 % | +16.85% |
Other
4.1
%
| 365 | 3.0 % | 536 | 4.1 % | +46.84% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 64 | 08/88/08 | |
Chief Executive Officer | 71 | 08/88/08 | |
Director of Finance/CFO | 54 | 01/03/01 | |
Melissa Lozner
CMP | Compliance Officer | - | 01/22/01 |
Bob McCowan
CTO | Chief Tech/Sci/R&D Officer | - | - |
Andrew Murphy
CTO | Chief Tech/Sci/R&D Officer | 66 | 01/99/01 |
Neil Stahl
CTO | Chief Tech/Sci/R&D Officer | 67 | 01/91/01 |
Patrice Gilooly
COO | Chief Operating Officer | - | 01/98/01 |
Chief Tech/Sci/R&D Officer | - | 01/19/01 | |
Mark Hudson
IRO | Public Communications Contact | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Christine Poon
BRD | Director/Board Member | 71 | 12/10/12 |
Chief Executive Officer | 71 | 08/88/08 | |
Michael Brown
BRD | Director/Board Member | 82 | 01/91/01 |
Joseph Goldstein
BRD | Director/Board Member | 83 | 01/91/01 |
George Sing
BRD | Director/Board Member | 74 | 08/88/08 |
Founder | 64 | 08/88/08 | |
Arthur Ryan
BRD | Director/Board Member | 81 | 01/03/01 |
N. Coles
BRD | Director/Board Member | 63 | 17/17/17 |
David Schenkein
BRD | Director/Board Member | 66 | 08/23/08 |
Bonnie Bassler
BRD | Director/Board Member | 61 | 12/16/12 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 10 | 1,818,146 | 0 | 0 | 77.81 % |
Stock B | 1 | 133,867,357 | 105,580,119 ( 78.87 %) | 25,500,000 ( 19.05 %) |
Company contact information
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
10591-6707, Tarrytown
+914 847 7000
http://www.regeneron.comGroup companies
Name | Category and Sector |
---|---|
Regeneron Ireland DAC
Regeneron Ireland DAC BiotechnologyHealth Technology Part of Regeneron Pharmaceuticals, Inc., Regeneron Ireland DAC is a leading Irish biotechnology company that uses science to develop new medicines for patients. The private company is located in Ireland. The company successfully manufactures a range of biopharmaceuticals for patients worldwide, including approved therapeutic proteins and those involved in clinical studies. |
Biotechnology
|
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.56% | 95.28B | |
-2.31% | 103B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B | |
-24.71% | 8.24B |
- Stock Market
- Equities
- REGN Stock
- Company Regeneron Pharmaceuticals, Inc.